PBAC's latest decision on Oxybutynin: Recommended with restriction (2023). Considered for Treatment of detrusor overactivity (overactive bladder) in patients unable to tolerate or swallow oral oxybutynin.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
4
first 2008
Submissions
4
2008 → 2023
Eligible population
Patients with detrusor overactivity (overactive bladder) who are unable to tolerate or swallow oral oxybutynin formulations.
Therapy area
Urology
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
No economic evaluation performed; this was an exempt item status review under subsection 84AH of the Act, not a full economic submission.
ICER (historical)
$15k/QALY across 3 submissions (2008–2009) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2008: Not recommended — ICER $45k/QALY
Nov 2008: Not recommended · Restricted — ICER $15k/QALY
Mar 2009: Recommended with restriction · Restricted Benefit — ICER $15k/QALY
Nov 2023: Recommended with restriction · Restricted